Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters










Database
Publication year range
1.
Psychopharmacology (Berl) ; 106 Suppl: S24-31, 1992.
Article in English | MEDLINE | ID: mdl-1546135

ABSTRACT

Interactions may occur on pharmacological or pharmacokinetic grounds. Both types of interactions are discussed in relationship with the pharmacological and pharmacokinetic data of moclobemide, a reversible MAO-inhibitor. A variety of interaction studies either designed more specifically as kinetic or as dynamic studies have been performed with moclobemide. The results of these studies are presented. In view of these results as well as in view of data stemming from clinical trials it can be concluded that apart from interactions with cimetidine and pethidine, moclobemide has been shown to be devoid of relevant interactions.


Subject(s)
Benzamides/pharmacology , Monoamine Oxidase Inhibitors/pharmacology , Animals , Benzamides/pharmacokinetics , Benzamides/therapeutic use , Drug Interactions , Humans , Moclobemide , Monoamine Oxidase Inhibitors/pharmacokinetics , Monoamine Oxidase Inhibitors/therapeutic use
2.
Psychopharmacology (Berl) ; 106 Suppl: S37-9, 1992.
Article in English | MEDLINE | ID: mdl-1546138

ABSTRACT

The effect of a protein-rich meal on the pharmacokinetics of moclobemide was studied after intravenous (75 mg) and oral (100 mg) administrations of this selective MAO-A inhibitor to eight healthy male volunteers. The meal chosen did not affect plasma concentration-time curves of the drug after oral administration apparently, because the influence of blood flow changes to the liver on hepatic first-pass metabolism (AUC increases) and on systemic clearance (AUC decreases) balance each other out.


Subject(s)
Benzamides/pharmacokinetics , Food , Adolescent , Adult , Biological Availability , Diet , Dietary Proteins/pharmacology , Humans , Indocyanine Green , Injections, Intravenous , Liver Circulation/drug effects , Liver Function Tests , Male , Moclobemide
3.
Psychopharmacology (Berl) ; 106 Suppl: S40-2, 1992.
Article in English | MEDLINE | ID: mdl-1546139

ABSTRACT

In a pharmacological screen on drug-drug interactions performed in laboratory animals moclobemide potentiated at high doses the antiphlogistic/anti-inflammatory activity of ibuprofen. Therefore, a study was undertaken to determine in healthy volunteers the faecal blood loss induced by multiple doses of ibuprofen (600 mg t.i.d.) in presence and absence of steady-state concentrations of concomitantly administered moclobemide (150 mg t.i.d.). The results show that multiple doses of moclobemide do not change faecal blood loss induced by ibuprofen. Furthermore, no clinically relevant pharmacokinetic interaction between the two drugs studied was detected.


Subject(s)
Benzamides/pharmacology , Gastrointestinal Hemorrhage/chemically induced , Ibuprofen/toxicity , Monoamine Oxidase Inhibitors/pharmacology , Occult Blood , Benzamides/pharmacokinetics , Double-Blind Method , Drug Synergism , Humans , Ibuprofen/pharmacokinetics , Moclobemide
4.
Psychopharmacology (Berl) ; 106 Suppl: S46-8, 1992.
Article in English | MEDLINE | ID: mdl-1347659

ABSTRACT

The effects of high single doses of moclobemide (300, 450 and 600 mg given at the end of a standardized meal) on plasma levels of several catecholamines and their deaminated metabolites, and on plasma levels of pituitary hormones were determined in eight healthy young male volunteers in a randomized, double-blind, placebo-controlled study. Assessment of the i.v. tyramine potentiation and determination of the plasma levels of moclobemide were also performed. The tyramine sensitivity factor at 2 h after dosing was about 2.1, with no significant differences between the doses used. The inhibitory activity of moclobemide on MAO-A was reflected in significant reductions of plasma concentrations of DHPG and 5-HIAA. No clear differences were detected between the moclobemide doses. Prolactin plasma concentrations were only slightly increased after the two higher doses. The plasma concentrations of moclobemide were very much in agreement with those found in previous studies under similar experimental conditions. Thus, single oral doses of 300, 450 and 600 mg moclobemide demonstrated marked inhibition of MAO-A activity, whereas a single dose of 300 mg induced a near-maximum effect.


Subject(s)
Benzamides/pharmacology , Catecholamines/metabolism , Monoamine Oxidase Inhibitors/pharmacology , Adult , Benzamides/pharmacokinetics , Blood Pressure/drug effects , Catecholamines/blood , Double-Blind Method , Humans , Male , Moclobemide , Monoamine Oxidase Inhibitors/pharmacokinetics , Neurotransmitter Agents/metabolism , Prolactin/blood , Tyramine/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...